Founded in 2005 by three senior scientists with complementary expertise in pharmaceutical, analytical and business development, the company offers a spectrum of R&D services focused exclusively on pharmaceutical oral solid dosage forms (i.e., tablets, capsules and granules) and cGMP services for phase I, II and early phase III studies. This expertise has led Corealis to develop over 800 drug products and manufacture and package over 350 different clinical trial materials for phase I, II and early phase III clinical trials. Eight drug products developed at Corealis have been approved for commercialization.

Located in the heart of the Biotech Scientific Park in Laval, Canada, Corealis has R&D laboratories, cGMP laboratories, and phase I, II, and early phase III clinical trial manufacturing packaging suites designed specifically for the formulation development and clinical supplies manufacturing of pharmaceutical oral solid dosage forms. The company has grown to over 40 employees today (with 23% of employees having a master’s degree or higher), led by a team of scientists, each with over 30 years of experience.

  • Investment date

    2022

  • Sector

    Biopharma Services

  • Transaction type

    Buy-Out

  • Growth theme

    Manufacturing capacity expansion / service offering expansion

  • Location

    Canada